The FDA established brief enforcement discretion periodsgrace periods to allow inventory to clearwhich ended on March 19, 2025, for tirzepatide and May 22, 2025, for semaglutide
These 3.8 million met the clinical criteria for the Bridge program, did not have a diagnosis of type 2 diabetes, sleep apnea or MASH, did not have a GLP-1 Part D covered prescription in 2023 and "could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026," the report added
This is exactly why so many people experience weight loss stalls on semaglutide and eventual weight regain after stopping
Individual weight loss outcomes with GLP-1 medications vary significantly regardless of whether you choose branded or compounded versions
Human and mouse elox3 have distinct substrate specificities: implications for their linkage with lipoxygenases in skin